COVID-19 treatments to enter the market with a hefty price tag

LOCAL RESEARCHERS FOUND. >> WE HAVE KNOWN FOR A WHILE THAT THE ANTIVIRAL DRUG CAN DRAMATICALLY REDUCE HOSPITALIZATION OR DEATH FOR THOSE NOT VACCINATED AGAINST COVID. THIS NEW DATA FOCUSES ON WHAT THE DRUG MEANS FOR PEOPLE WHO HAVE GOTTEN THEIR COVER SHOTS AND THEIR SIGNIFICANT BENEFIT. RESEARCHERS AT MASS GENERAL BRIGHAM FOUND TAX LIMIT CAN CUT THE RISK OF HOSPITALIZATION AND DEATH BY NEARLY HALF AMONG THOSE WHO ARE VACCINATED AGAINST COVID. ONE OF THE STUDY AUTHORS SAYS THAT KNOWING THAT PAXLOVID CAN STILL HELP REDUCE HOSPITALIZATIONS, EVEN WHEN MORE PEOPLE ARE VACCINATED IS CRITICAL. >> WE ESTIMATE WE COULD AVOID AT LEAST A QUARTER OF ALL ADMISSIONS TO THE HOSPITAL FOR COVID OVER THIS NEXT WAVE. IF WE CAN DO A BETTER JOB OF GETTING BACK. PARTICULARLY THIS HIGH-RISK MOVE FOR PEOPLE TO MAKE SURE THAT THEY ARE ABLE TO TEST THEMSELVES PROPERLY AT HOME AND LET US KNOW THEY ARE POSITIVE. SO WE CAN PROVIDE THEM THERAPY. >> THAT IS KEY, MAKING SURE PEOPLE ARE TESTING WHEN THEY ARE SICK SO THEY CAN REACH OUT TO THEIR DOCTOR AND SEE IF PAXLOVID IS FOR THEM. THIS IS IMPORTANT FOR ANYONE IN THE HIGH RISK CATEGORY INCLUDING PEOPLE WHO HAVE NOT BEEN BOOSTED. AS FOR REBOUND INFECTIONS THAT WE HAVE HEARD A LOT ABOUT, DR. DRYDEN PETERSON SAYS THOSE ARE LESS SEVERE AND LESS LIKELY TO LAND YOU IN THE HOSPITAL OR WORSE FOR HIGH-RISK PATIENTS HE SAYS THAT STILL MEA

The COVID-19 treatments millions of Americans have taken for free from the federal government will enter the private market next week with a hefty price tag.Pharmaceutical giant Pfizer is setting the price for a five-day treatment of Paxlovid at $1,390, but Americans can still access the pills at no cost -- for now. The less commonly used COVID-19 treatment Lagevrio, manufactured by Merck, also will hit the market next week.Millions of free, taxpayer-funded courses of the pills will remain at pharmacies, hospitals and doctor's offices across the country, U.S. Health and Human Services officials said Friday. People on private insurance may start to notice copays for the treatments once their pharmacy or doctor's office runs out of the COVID-19 treatments they received from the government.The U.S. government initially inked a deal with Pfizer to pay more than $5 billion for 10 million courses of Paxlovid in 2021.Under a new agreement, reached last month between Pfizer and the federal government, people on Medicaid, Medicare or those who are without medical insurance will not pay any out-of-pocket costs for the treatment through the end of next year. Pfizer will also offer copay assistance for the treatment through 2028. The Department of Veterans Affairs, the Department of Defense and Indian Health Service will still be able to access Paxlovid the government has on hand. The government will also get 1 million treatment courses to keep in its stockpile.Suppliers to pharmacies, doctor바카라 게임 웹사이트�s offices and hospitals can begin ordering the treatments from the drug companies starting next week.바카라 게임 웹사이트�Pfizer is committed to a smooth commercial transition and is working collaboratively with the U.S. government and health care stakeholders to ensure broad and equitable access to this important medicine for all eligible patients,바카라 게임 웹사이트� the company said in an emailed statement to The Associated Press.Paxlovid has been used to treat COVID-19 since 2021, but the Food and Drug Administration granted full approval earlier this year for it to be used on adults with coronavirus who face high risks of hospitalization or death. That group typically includes older adults and those with medical conditions like diabetes, asthma and obesity.Full-year revenue for Paxlovid and Pfizer's COVID-19 vaccine, Comirnaty, is expected to be approximately $12.5 billion.Merck has not confirmed a list price yet for its Lagevrio treatment but said in a statement to AP that it will also offer the treatment free to patients 바카라 게임 웹사이트�who, without assistance, could not otherwise afford the product.바카라 게임 웹사이트�_____ Associated Press reporter Tom Murphy in Indianapolis contributed to this report.

WASHINGTON —

The COVID-19 treatments millions of Americans have taken for free from the federal government will enter the private market next week with a hefty price tag.

Pharmaceutical giant Pfizer is setting the price for a five-day treatment of Paxlovid at $1,390, but Americans can still access the pills at no cost -- for now. The less commonly used COVID-19 treatment Lagevrio, manufactured by Merck, also will hit the market next week.

Millions of free, taxpayer-funded courses of the pills will remain at pharmacies, hospitals and doctor's offices across the country, U.S. Health and Human Services officials said Friday. People on private insurance may start to notice copays for the treatments once their pharmacy or doctor's office runs out of the COVID-19 treatments they received from the government.

The U.S. government initially inked a deal with Pfizer to pay more than $5 billion for 10 million courses of Paxlovid in 2021.

Under a new agreement, reached last month between Pfizer and the federal government, people on Medicaid, Medicare or those who are without medical insurance will not pay any out-of-pocket costs for the treatment through the end of next year. Pfizer will also offer copay assistance for the treatment through 2028. The Department of Veterans Affairs, the Department of Defense and Indian Health Service will still be able to access Paxlovid the government has on hand. The .

Suppliers to pharmacies, doctor바카라 게임 웹사이트�s offices and hospitals can begin ordering the treatments from the drug companies starting next week.

바카라 게임 웹사이트�Pfizer is committed to a smooth commercial transition and is working collaboratively with the U.S. government and health care stakeholders to ensure broad and equitable access to this important medicine for all eligible patients,바카라 게임 웹사이트� the company said in an emailed statement to The Associated Press.

Paxlovid has been used to treat COVID-19 since 2021, but the Food and Drug Administration granted full approval earlier this year for it to be used on adults with coronavirus who face high risks of hospitalization or death. That group typically includes older adults and those with medical conditions like diabetes, asthma and obesity.

Full-year revenue for Paxlovid and Pfizer's COVID-19 vaccine, Comirnaty, is expected to be approximately $12.5 billion.

Merck has not confirmed a list price yet for its Lagevrio treatment but said in a statement to AP that it will also offer the treatment free to patients 바카라 게임 웹사이트�who, without assistance, could not otherwise afford the product.바카라 게임 웹사이트�

_____

Associated Press reporter Tom Murphy in Indianapolis contributed to this report.

COVID-19 treatments to enter the market with a hefty price tag

Share

Share

Share

Top Picks